Duodenal Ulcer Treatment Market Report 2024

The duodenal ulcer treatment market size has grown strongly in recent years. It will grow from $93.42 billion in 2023 to $99.99 billion in 2024 at a compound annual growth rate (CAGR) of 7%. The increase observed in the past can be linked to several factors, including a rising preference among patients for non-invasive treatments, heightened awareness of gastrointestinal health, a growing number of cigarette smokers, more consumers of alcohol and tobacco, and a greater integration of digital health solutions.

The duodenal ulcer treatment market size is expected to see strong growth in the next few years. It will grow to $133.1 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The anticipated growth in the forecast period is expected due to a rise in the prevalence of diseases, an expansion of medical infrastructure and healthcare facilities, increased awareness of treatment options, a growing inclination towards minimally invasive procedures, and enhanced government efforts to promote awareness. Key trends to watch for during this period include advancements in technology, the incorporation of probiotics, the use of telemedicine, nutritional therapy, and the integration of evidence-based practices.

The anticipated growth in the duodenal ulcer treatment market is linked to the rising number of cigarette smokers. Cigarette smokers are individuals who regularly consume cigarettes, which are small rolls of paper filled with tobacco that are smoked by inhaling and exhaling the smoke. The rise in cigarette smoking is influenced by cultural factors, public policies, and socioeconomic conditions. Managing duodenal ulcers in smokers requires a thorough approach, including ulcer-specific treatments, smoking cessation programs, lifestyle changes, and continuous monitoring to promote healing and prevent recurrence. For example, data from the Office for National Statistics in the UK revealed that in 2022, approximately 6.4 million adults over 18 were cigarette smokers, representing 12.9% of the population. Additionally, among the 16 to 24 age group, e-cigarette use rose to 15.5% in 2022, up from 11.1% in 2021. This increase in smoking rates is contributing to the expansion of the duodenal ulcer treatment market.

Key players in the duodenal ulcer treatment market are concentrating on creating advanced products, such as combination kits for treating both duodenal ulcers and H. pylori infections, to improve ulcer healing. A combination kit generally involves a therapy that includes medications designed to heal the ulcer and eliminate the H. pylori bacteria. For example, in April 2023, Akums Drugs and Pharmaceutical Limited, an Indian pharmaceutical company, introduced an innovative combination kit for duodenal ulcers related to H. pylori infection. This kit combines three effective medications - amoxicillin, clarithromycin, and esomeprazole - to combat H. pylori bacteria and decrease gastric acid production, addressing the main causes of duodenal ulcers. The Central Drugs Standard Control Organization (CDSCO) has approved this kit for treating duodenal ulcers and eliminating H. pylori in patients with active or healed peptic ulcers.

In June 2022, Glenmark Pharmaceuticals Ltd., an Indian company specializing in duodenal ulcer treatments, acquired over-the-counter (OTC) drug products from Wockhardt Limited for an undisclosed sum. This acquisition highlights Glenmark’s ongoing efforts to expand in the US OTC market and demonstrates its dedication to providing affordable, high-quality medications. Wockhardt Limited, also based in India, is a pharmaceutical and biotechnology company that offers treatments for duodenal ulcers.

Major companies operating in the duodenal ulcer treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A, Bristol-Myers Squibb, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz AG, Sun Pharmaceutical Industries Limited, Eisai Co. Ltd., Aurobindo Pharma Limited, Cipla Inc., Dr. Reddy's Laboratories Limited, Intas Pharmaceuticals Limited, Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Limited, Jubilant Pharma Limited, Torrent Pharmaceuticals Limited.

North America was the largest region in the duodenal ulcer treatment market in 2023. The regions covered in the duodenal ulcer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the duodenal ulcer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Duodenal ulcer treatment encompasses the methods used to heal and manage ulcers located in the duodenum, the initial segment of the small intestine. This treatment typically includes a mix of medications aimed at decreasing acid production and fostering healing, lifestyle modifications, and occasionally, treatments to eliminate Helicobacter pylori bacteria, which is a frequent cause of duodenal ulcers.

The primary treatment options for duodenal ulcers are antibiotics, proton pump inhibitors, antacids, potassium-competitive acid blockers, H2-antagonists, ulcer-protective drugs, and surgery. Antacids are specifically used to address bacterial infections such as those caused by Helicobacter pylori, which can contribute to the development of duodenal ulcers. This aids in eradicating the bacterial infection and facilitating proper ulcer healing. These treatments are applicable to both adults and the elderly, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The duodenal ulcer treatment market research report is one of a series of new reports that provides duodenal ulcer treatment market statistics, including duodenal ulcer treatment industry global market size, regional shares, competitors with a duodenal ulcer treatment market share, detailed duodenal ulcer treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the duodenal ulcer treatment industry. This duodenal ulcer treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The duodenal ulcer treatment market consists of revenues earned by entities by providing services such as endoscopic therapies, follow-up care, and lifestyle and dietary changes. The market value includes the value of related goods sold by the service provider or included within the service offering. The duodenal ulcer treatment market also includes sales of endoscopic devices, surgical instruments, H2-receptor antagonists, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.